Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1

被引：0
|
作者：
van Wesemael, Tineke [1 ]
Borgers, Jessica [2 ]
Gelderman, Kyra [3 ]
Verdegaal, Els [4 ]
Korse, C. M. [5 ]
Welters, M. J. P. [6 ]
Kapiteijn, Ellen [7 ]
van Houdt, W. J. [2 ]
van der Burg, Sjoerd [6 ]
Toes, Rene [1 ]
Thienen, J. V. [2 ]
Haanen, John [2 ]
van der Woude, Diane [1 ]
机构：
[1] Leiden Univ Med Ctr, Leiden, Netherlands
[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[3] Sanquin Diagnost Serv, Amsterdam, Netherlands
[4] Leiden Univ Med Ctr, Oncode Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Netherlands Canc Inst, Dept Lab Med, Antoni Van Leeuwenhoek, Amsterdam, Netherlands
[6] Leiden Univ Med Ctr, Oncode Inst, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ Med Ctr, Dept Med Oncol, Leiden, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2510
引用
收藏
页码：4977 / 4979
页数：3
相关论文
共 50 条
  • [21] The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
    Chiao-En Wu
    Chan-Keng Yang
    Meng-Ting Peng
    Pei-Wei Huang
    Ching-Fu Chang
    Kun-Yun Yeh
    Chun-Bing Chen
    Chih-Liang Wang
    Chao-Wei Hsu
    I-Wen Chen
    Cheng-Tao Lin
    Shir-Hwa Ueng
    Gigin Lin
    Yu-Fen Lin
    Chi-Yuan Cheng
    John Wen-Cheng Chang
    BMC Cancer, 20
  • [22] The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
    Wu, Chiao-En
    Yang, Chan-Keng
    Peng, Meng-Ting
    Huang, Pei-Wei
    Chang, Ching-Fu
    Yeh, Kun-Yun
    Chen, Chun-Bing
    Wang, Chih-Liang
    Hsu, Chao-Wei
    Chen, I-Wen
    Lin, Cheng-Tao
    Ueng, Shir-Hwa
    Lin, Gigin
    Lin, Yu-Fen
    Cheng, Chi-Yuan
    Chang, John Wen-Cheng
    BMC CANCER, 2020, 20 (01)
  • [23] Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs)
    Rogado Revuelta, Jacobo
    Romero-Laorden, Nuria
    Sanchez Torres, Jose Miguel
    Pacheco-Barcia, Vilma
    Ballesteros, Anabel
    Maria Ramos-Levi, Ana
    Arranz, Reyes
    Lorenzo, Alicia
    Gullon, Pedro
    Garrido Garcia, Ana
    Maria Serra, Jose
    Donnay, Olga
    Adrados, Magdalena
    Costas, Pablo
    Aspa, Javier
    Alfranca, Arantza
    Fenor De la Maza, Maria Dolores
    Mondejar, Rebeca
    Colomer, Ramon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Immune-related adverse events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients
    Rogado, J.
    Romero Laorden, N.
    Sanchez Torres, J. M.
    Ballesteros Garcia, A. I.
    Pacheco-Barcia, V. E.
    Arranz, R.
    Mondejar Solis, R.
    Gullon, P.
    Lorenzo, A.
    Colomer Bosch, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Autoantibody positivity predicts severity of ICI-associated rheumatic immune-related adverse events
    Reactions Weekly, 2022, 1916 (1) : 7 - 7
  • [26] Immune-related adverse event recurrence with anti-PD-1 therapy
    Reactions Weekly, 2020, 1816 (1) : 8 - 8
  • [27] Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients
    Huang, Y.
    Soon, Y. Y.
    Aminkeng, F.
    Tay, S. H.
    Ang, Y.
    Goh, B. C.
    Wong, A.
    Soo, R. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S577 - S577
  • [28] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Pollack, M. H.
    Betof, A.
    Dearden, H.
    Rapazzo, K.
    Valentine, I.
    Brohl, A. S.
    Ancell, K. K.
    Long, G. V.
    Menzies, A. M.
    Eroglu, Z.
    Johnson, D. B.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
  • [29] Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
    Kim, Kyung Hwan
    Hur, Joon Young
    Cho, Jinhyun
    Ku, Bo Mi
    Koh, Jiae
    Koh, June Young
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    Shin, Eui-Cheol
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [30] Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma
    Patrinely, J. Randall, Jr.
    Johnson, Rebecca
    Lawless, Aleigha R.
    Bhave, Prachi
    Sawyers, Amelia
    Dimitrova, Maya
    Yeoh, Hui Ling
    Palmeri, Marisa
    Ye, Fei
    Fan, Run
    Davis, Elizabeth J.
    Rapisuwon, Suthee
    Long, Georgina V.
    Haydon, Andrew
    Osman, Iman
    Mehnert, Janice M.
    Carlino, Matteo S.
    Sullivan, Ryan J.
    Menzies, Alexander M.
    Johnson, Douglas B.
    JAMA ONCOLOGY, 2021, 7 (05) : 744 - 748
12345